PTS Diagnostics to Consolidate Manufacturing Operations with Closure of Sunnyvale Facility
PTS Diagnostics, Inc., a leader in point-of-care testing solutions for diabetes and cardiovascular health management, has announced plans to close its Sunnyvale, California manufacturing facility as part of a strategic consolidation effort. The company, which specializes in producing innovative, easy-to-use blood testing devices, will begin the closure process on December 5, 2025, with the final shutdown anticipated to occur on or around March 31, 2026.
The move marks a significant operational shift for the company, which has maintained a manufacturing presence in Sunnyvale since January 2014. The facility has played a crucial role in producing PTS Diagnostics’ A1CNow® product line—a point-of-care test that enables healthcare providers and patients to measure hemoglobin A1C levels quickly and conveniently, providing valuable insights into long-term glucose control. Over the years, the Sunnyvale team has contributed substantially to the company’s mission of improving health outcomes for people living with diabetes across the globe.
Strategic Consolidation for Operational Efficiency
According to PTS Diagnostics, the decision to close the Sunnyvale facility is driven by the company’s ongoing efforts to streamline operations and improve efficiency across its manufacturing network. The company’s Whitestown, Indiana facility, which opened in July 2019, has now reached full operational capacity and will absorb the manufacturing functions currently carried out in Sunnyvale.
This strategic consolidation will bring together the production of both the A1CNow® and CardioChek® product lines into a single centralized facility. The CardioChek system is another cornerstone of PTS Diagnostics’ portfolio, offering rapid, portable lipid and glucose testing that supports cardiovascular disease risk assessment. By uniting the production of these flagship products under one roof, PTS Diagnostics aims to enhance coordination, reduce redundancy, and achieve greater manufacturing scalability.
The Whitestown facility was designed with expansion and flexibility in mind. Its modern infrastructure and advanced manufacturing technologies provide PTS Diagnostics with the capacity to meet growing global demand while ensuring consistent product quality and regulatory compliance. The integration of all major production lines into this site is expected to generate significant operational synergies, supporting the company’s long-term growth and innovation strategy.
Commitment to Employees and the Sunnyvale Community
While the decision to close the Sunnyvale plant is rooted in operational and strategic considerations, PTS Diagnostics emphasized its deep appreciation for the contributions of its California-based employees and the community that has supported its operations for more than a decade.
“We express appreciation to all our employees. Their dedication and commitment to the production of A1CNow has positively impacted outcomes and quality of life for persons with diabetes in the global communities that we serve,” said Jonathan Chapman, President and CEO of PTS Diagnostics. “We are sincerely grateful to the Sunnyvale community for being our home for the past eleven years. The impact of their efforts has reached millions of patients worldwide.”
The company noted that it will work closely with affected employees during the transition period. While specific details regarding employee support programs were not disclosed, similar consolidation efforts in the medical device industry often include relocation opportunities, severance packages, and job placement assistance. PTS Diagnostics’ leadership underscored its commitment to ensuring a smooth and respectful transition for all personnel involved.
A Decade of Innovation and Impact in Sunnyvale
Since establishing its Sunnyvale facility in January 2014, PTS Diagnostics has built a strong local presence in Silicon Valley—a region known for its innovation, talent, and technological leadership. The site became a hub for manufacturing the company’s A1CNow® product line, which provides rapid, accurate testing for hemoglobin A1C levels using a small blood sample. The device’s portability and ease of use have made it an invaluable tool for physicians, clinics, and patients managing diabetes both in the United States and internationally.
During its operational years in Sunnyvale, the facility played an instrumental role in advancing PTS Diagnostics’ global footprint. The products manufactured there have been distributed to over 130 countries and have contributed to the company’s reputation for reliability and accuracy in point-of-care testing. Employees at the Sunnyvale site were also part of continuous improvement initiatives, ensuring adherence to stringent quality standards in compliance with global regulatory requirements.
Positioning for the Future
The closure of the Sunnyvale plant reflects a broader strategic vision for PTS Diagnostics as it continues to evolve in a competitive and rapidly changing healthcare landscape. The consolidation of manufacturing operations is expected to provide several key advantages:
- Improved Efficiency and Cost Optimization:
Centralizing production at the Whitestown facility will streamline logistics and supply chain processes, reduce duplication of effort, and lower overhead costs associated with maintaining multiple sites. - Enhanced Product Integration:
By producing both A1CNow® and CardioChek® in one location, the company can more effectively coordinate manufacturing, quality control, and distribution, enabling faster response to market needs. - Scalability for Growth:
The Whitestown plant’s state-of-the-art infrastructure allows for scalable production to accommodate future product launches and increased demand for diagnostic devices as healthcare providers increasingly shift toward point-of-care solutions. - Sustainability and Environmental Impact:
Consolidating manufacturing operations also aligns with PTS Diagnostics’ environmental objectives by reducing its overall carbon footprint through optimized energy usage, reduced transportation, and improved waste management practices.
Continued Focus on Global Health
PTS Diagnostics remains committed to its mission of improving global health outcomes by providing innovative diagnostic tools that empower patients and healthcare professionals alike. With the rising prevalence of diabetes and cardiovascular disease worldwide, demand for rapid and reliable diagnostic testing is growing steadily.
Through its comprehensive portfolio—which includes A1CNow+®, A1CNow Self Check®, and CardioChek Plus®—the company supports early detection, disease monitoring, and risk assessment, helping clinicians make informed treatment decisions in real time. These solutions align with the global push toward more accessible, cost-effective, and patient-centered care.
By consolidating its manufacturing in Indiana, PTS Diagnostics is positioning itself to meet these demands more effectively, ensuring product consistency, faster delivery times, and continued innovation in test development and production processes.
A Legacy of Innovation and Service
Founded with a mission to bring laboratory-quality diagnostic testing to the point of care, PTS Diagnostics has become a trusted name in the medical device industry. The company’s products are used in hospitals, physician offices, pharmacies, and remote care settings worldwide. Over the years, PTS Diagnostics has built strong partnerships with healthcare organizations, distributors, and public health institutions, reinforcing its reputation for quality and reliability.
While the closure of the Sunnyvale facility marks the end of a meaningful chapter in the company’s history, it also opens the door to a new era of operational excellence and growth. The decision underscores the company’s adaptability and focus on sustaining its leadership position in the evolving diagnostics market.
